The phase III KEYNOTE-355 trial investigating Keytruda in combination with chemotherapy met one of its dual primary endpoints of progression-free survival in patients with metastatic triple-negative breast cancer whose tumors expressed PD-L1 (Combined Positive Score [CPS] ≥10).
The phase III PROSPER trial, which evaluated Xtandi (enzalutamide) plus androgen deprivation therapy versus placebo plus ADT in men with non-metastatic castration-resistant prostate cancer, demonstrated a statistically significant improvement in overall survival in patients with nmCRPC who were treated with Xtandi plus ADT.
A team of scientists at the Keck School of Medicine of USC have found people who vape exhibit similar chemical modifications in their overall genome and in parts of their DNA as people who smoke cigarettes.
A program at Ohio State is trying to make use of cancer drugs that would otherwise go to waste.
The Neuroendocrine Tumor Research Foundation provided $3.5 million in neuroendocrine tumor research grants to 12 projects to find more precise treatments for the cancer.
Jeff Boyd was named vice president, chief scientific officer and director of the Cancer Institute's Center for Genomic Medicine at The Northwell Health Cancer Institute. He will also hold an appointment as professor and member of the Cold Spring Harbor Laboratory Cancer Center.
Colleen McBride was named associate director for community outreach and engagement at Winship Cancer Institute of Emory University.
Zelia M. Correa, an expert in ocular oncology, has joined Sylvester Comprehensive Cancer Center and Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine as co-director of the ocular oncology service.
Karyn Aalami Goodman was named associate director for clinical research at Mount Sinai's The Tisch Cancer Institute. She is also professor and vice chair for research and quality in the Department of Radiation Oncology.
Lillian L. Siu will receive the European Society for Medical Oncology's TAT 2020 Honorary Award for her contributions in the development of new anticancer drugs, particularly with respect to phase I trials in head and neck malignancies.
